ShareSoc Growth Company Seminar (Hybrid Event), 13 November 2025, 5pm

Join us on 13 November for our autumn hybrid event in London. This event will consist of an in-person seminar in London, which will also be streamed live (and recorded), allowing members to watch virtually.

Please register to attend the event in person or to watch virtually, using the 2 different links below.

Each company will present for 25 minutes and then take your questions for another 15 minutes. All attendees (whether attending in person or virtually) will be able to ask questions and those attending the seminar will be able to network with company directors and fellow investors over drinks and a buffet.

Click here to register for the in-person seminar in London.
Click here to join the virtual event.

Event registration opens at 4.30 pm and presentations commence at 5.00 pm.
There will be a networking opportunity after the presentations.

Companies Presenting

Bioventix (BVXP)

Bioventix creates, manufactures and supplies high affinity sheep monoclonal antibodies (SMAs) for use in diagnostic applications.  Bioventix antibodies are preferred for use when they confer an improved test performance compared to other available antibodies.

Most of Bioventix’s antibodies are used on blood-testing machines installed in hospitals and other laboratories around the world.  Bioventix makes antibodies using its SMA technology for supply to diagnostic companies for subsequent manufacture into reagent packs used on blood-testing machines.  These blood-testing machines are supplied by large multinational in vitro diagnostics (IVD) companies such as Roche Diagnostics, Siemens Healthineers, Abbott Diagnostics & Beckman Coulter.  Antibody-based blood tests are used to help diagnose many different conditions including, amongst others, heart disease, thyroid function, fertility, infectious disease and cancer.

Presenter:
Peter Harrison- CEO
Peter is 65 years old and has ~30 years’ experience of antibody technology at Celltech, KS Biomedix & Bioventix.

TheraCryf plc (TCF)

TheraCryf is the clinical stage drug development company focussing on brain disorders. The Company has a broad clinical and preclinical pipeline in indications including addiction, anxiety, fatigue, narcolepsy, glioblastoma* and neurodevelopmental disorders (*orphan indication).

Its strategy is to generate compelling data sets to preclinical and/or clinical proof of concept and partner its clinical programmes with mid-size to large pharma for larger trials and commercialisation. It also has industry partnerships with companies including Stalicla SA, in neurodevelopmental disorders.

Presenters:
Dr Huw Jones, CEO
Huw has over 30 years’ experience of leadership roles in public and private R&D-based companies within the biotechnology and pharmaceutical sector, with a particular focus on preclinical and clinical drug development, dilutive and non-dilutive financing and business development. Most recently he was a Non-executive Director of Ixaka Ltd and Chairman of Chronos Therapeutics Ltd. Huw is a non-executive Director of biotech industry body OBN. Huw holds a PhD in pharmacology from the University of Birmingham, UK

Dr Helen Kuhlman, COO
Helen has over 20 years’ experience in life science beginning her career as a research scientist at Cambridge Antibody Technology and Domantis, before transitioning into strategy and business development roles. She has been an active proponent of the UK biotech innovation ecosystem, leading the creation and delivery of the £180m Biomedical Catalyst competitive grant scheme, whilst at Innovate UK. In addition to her role in TheraCryf she is an Operating Advisor with SymBiosis Capital Management, a US based healthcare focused venture fund, and an independent board member of the University Commercialization Executive Board at the University of Bath.

Speaker

Dr Arron Aatkar, Healthcare Analyst at Edison

Arron joined Edison’s healthcare team as an equity analyst in January 2023 and has covered over 30 companies within the sector since joining. Prior to this, he worked at GSK for four years and completed a PhD in chemical biology through the GSK/University of Strathclyde Collaborative PhD Programme. During this time, he conducted extensive research into novel therapeutic technologies, with a particular focus on covalent drug discovery, oncology, and various rare diseases. Arron also holds an integrated MSci degree in chemistry from the University of Bristol.

Dr Aatkar will explore the current positioning of the healthcare sector, highlight the key fundamental drivers behind its growth, and uncover innovation themes that are creating compelling investment opportunities.